EXACT Sciences (NASDAQ:EXAS)‘s stock had its “buy” rating restated by William Blair in a report issued on Tuesday, TipRanks reports.

Several other equities research analysts have also recently weighed in on the company. BidaskClub cut EXACT Sciences from a “buy” rating to a “hold” rating in a report on Wednesday, July 17th. Zacks Investment Research raised EXACT Sciences from a “hold” rating to a “buy” rating and set a $129.00 price target on the stock in a research note on Thursday, August 1st. Craig Hallum boosted their price objective on EXACT Sciences from $115.00 to $127.00 and gave the company a “buy” rating in a research report on Tuesday, July 30th. UBS Group increased their price objective on EXACT Sciences from $120.00 to $143.00 and gave the company a “buy” rating in a research note on Thursday, August 1st. Finally, Cowen raised their target price on shares of EXACT Sciences from $125.00 to $135.00 and gave the stock an “outperform” rating in a report on Monday, July 29th. They noted that the move was a valuation call. One equities research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $126.22.

EXACT Sciences stock traded down $0.41 during mid-day trading on Tuesday, hitting $108.60. The company’s stock had a trading volume of 1,558,884 shares, compared to its average volume of 1,715,002. The business has a 50 day moving average price of $117.39 and a 200-day moving average price of $104.72. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.79 and a quick ratio of 2.69. EXACT Sciences has a 12 month low of $53.06 and a 12 month high of $123.99. The stock has a market cap of $14.08 billion, a price-to-earnings ratio of -79.85 and a beta of 1.49.

EXACT Sciences (NASDAQ:EXAS) last released its quarterly earnings data on Monday, July 29th. The medical research company reported ($0.30) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.56) by $0.26. EXACT Sciences had a negative return on equity of 28.90% and a negative net margin of 35.43%. The firm had revenue of $199.87 million for the quarter, compared to the consensus estimate of $182.18 million. During the same quarter in the previous year, the business earned ($0.30) earnings per share. The company’s quarterly revenue was up 94.3% on a year-over-year basis. On average, equities research analysts expect that EXACT Sciences will post -1.74 earnings per share for the current fiscal year.

In related news, CFO Jeffrey Thomas Elliott sold 9,845 shares of the firm’s stock in a transaction on Tuesday, July 30th. The stock was sold at an average price of $105.60, for a total value of $1,039,632.00. Following the completion of the sale, the chief financial officer now owns 41,012 shares of the company’s stock, valued at $4,330,867.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Katherine S. Zanotti sold 1,744 shares of EXACT Sciences stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $117.93, for a total transaction of $205,669.92. Following the completion of the sale, the director now owns 42,844 shares in the company, valued at approximately $5,052,592.92. The disclosure for this sale can be found here. 2.20% of the stock is owned by company insiders.

Institutional investors have recently modified their holdings of the business. NumerixS Investment Technologies Inc purchased a new stake in shares of EXACT Sciences in the 2nd quarter worth about $35,000. Harvest Fund Management Co. Ltd bought a new stake in EXACT Sciences during the 2nd quarter valued at approximately $43,000. Coastal Investment Advisors Inc. boosted its position in EXACT Sciences by 95.5% during the 2nd quarter. Coastal Investment Advisors Inc. now owns 391 shares of the medical research company’s stock valued at $47,000 after acquiring an additional 191 shares in the last quarter. Mosaic Family Wealth LLC purchased a new position in shares of EXACT Sciences during the 1st quarter worth approximately $37,000. Finally, NEXT Financial Group Inc purchased a new position in shares of EXACT Sciences during the 2nd quarter worth approximately $50,000. 89.56% of the stock is currently owned by institutional investors and hedge funds.

EXACT Sciences Company Profile

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

Further Reading: What are the FAANG Stocks?

Analyst Recommendations for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.